Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 13/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13211348 | 0.83 | AR (0.51) | ARSLC22A12PGRKIF11 | |
| SCHEMBL1762353 | 0.83 | TRPV4 (0.50) | ARSLC22A12PGR | |
| SCHEMBL30105299 | 0.83 | TRPV4 (0.50) | ARSLC22A12PGR | |
| Hydrochloric Acid SCHEMBL28333364 | 0.82 | AR (0.51) | ARSLC22A12PGR | |
| SCHEMBL21335068 | 0.81 | SLC22A12 (0.52) | ARSLC22A12PGR | |
| SCHEMBL8488892 | 0.80 | AR (0.51) | ARSLC22A12PGR | |
| SCHEMBL17776383 | 0.80 | KIF11 (0.51) | ARSLC22A12PGRKIF11 | |
| SCHEMBL7082554 | 0.78 | KIF11 (0.59) | KIF11CA12CA1CA2CA9 | |
| SCHEMBL23579849 | 0.77 | CA2 (0.56) | CA12CA1CA2CA9 | |
| SCHEMBL23877136 | 0.77 | AR (0.51) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190352291-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2019-11-21 | — | — | US | disclosed |
| US-10407416-B2 | Kappa opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180016266-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2018-01-18 | — | — | US | disclosed |
| WO-2014210436-A2 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS (US) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352291-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | OPRK1, OPRD1, OPRM1 | AR 593/4885SLC22A12 2376/4885PGR 570/4885 |
| US-20180016266-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | OPRK1, OPRD1, OPRL1 | AR 382/4885SLC22A12 2796/4885PGR 397/4885 |
| US-10407416-B2 | Kappa opioid agonists and uses thereof | OPRK1, OPRD1, OPRL1 | AR 382/4885SLC22A12 2796/4885PGR 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.